baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Avadel Pharmaceuticals plc/ IE00BDGMC594 /

6/5/2024 6:30:22 PM	Chg. -0.55	Volume	Bid-	Ask-	High	Low
14.92USD	-3.56%	13,345 Turnover: 200,983.36	-Bid Size: -	-Ask Size: -	15.37	14.84

GlobeNewswire 5/30 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire 5/22 Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CII...

GlobeNewswire 5/21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 5/8 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 5/1 Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results...

GlobeNewswire 4/1 Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

GlobeNewswire 3/5 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire 3/4 Avadel Pharmaceuticals Issues Statement On Patent Litigation

GlobeNewswire 3/4 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Finan...

GlobeNewswire 2/26 Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Fi...

GlobeNewswire 1/8 Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Qu...

GlobeNewswire 11/8/2023 Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire 11/7/2023 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire 10/30/2023 Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on N...

GlobeNewswire 10/20/2023 Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for e...

GlobeNewswire 10/5/2023 Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

GlobeNewswire 8/31/2023 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire 3/17/2022 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Finan...

GlobeNewswire 3/14/2022 Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate ...

GlobeNewswire 3/11/2022 Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing ...

GlobeNewswire 3/10/2022 Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire 3/1/2022 Avadel to Present New Clinical Data at World Sleep 2022

GlobeNewswire 2/14/2022 Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

GlobeNewswire 2/10/2022 Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire 11/22/2021 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals plc/ IE00BDGMC594 /

If you wish to receive reply to your feedback, please provide your email address.